T1	Participants 587 607	pharmacokinetic (PK)
T2	Participants 626 648	BDDrFVIII formulations
T3	Participants 830 860	in patients with haemophilia A
T4	Participants 900 971	series of blood samples were collected over a period of 48 h after i.v.
T5	Participants 972 1021	administration of each of the FVIII preparations.
